Anthropic to develop drugs for neglected diseases using Claude AI

Anthropic enters drug development

Anthropic announced this week it will develop its own pharmaceutical treatments for neglected diseases, marking one of the most direct moves by a major AI company into actual drug creation rather than just selling tools to drugmakers.

The announcement came at an event called "The Briefing: AI for Science," where Anthropic unveiled Claude Science, described as an AI workbench that consolidates fragmented scientific tools and datasets into a single environment while generating figures and visualizations. Eric Kauderer-Abrams, Anthropic's head of life sciences, said the company would focus on discovering treatments for neglected diseases, though he provided no specifics about which conditions or how the company would proceed if it identifies promising drug candidates.

According to The Verge, which first reported the details, Anthropic did not respond to requests for clarification on what diseases it plans to target, whether it would partner with other companies for laboratory work, animal testing, clinical trials, or manufacturing.

Why it matters

Anthropic's dual role as both software vendor and potential competitor creates an unusual dynamic in the pharmaceutical industry. The company already sells AI tools to biotech and pharma customers, and now plans to develop drugs that could compete with products from those same clients. This tension reflects broader questions about how AI companies will monetize their life sciences ambitions and whether they can successfully navigate the complex, heavily regulated path from computational discovery to approved therapies.

A crowded field

Anthropic joins an increasingly competitive landscape. OpenAI, Amazon, and Google have all launched life sciences tools and platforms. The field also includes AI-native drug companies like Insilico, Google DeepMind's spinout Isomorphic Labs, numerous biotech startups, and traditional pharmaceutical giants building or acquiring their own AI capabilities.

Experts told The Verge that the lack of specificity in Anthropic's plans reflects broader uncertainty around the AI drug development boom itself. While AI companies have been eager to court science and pharmaceutical customers, the path from algorithmic predictions to drugs that reach patients remains long and uncertain.

Anthropic has positioned Claude Science around what it calls AI's potential to "dramatically accelerate the pace of scientific discovery and the development of healthcare interventions," and highlighted a roster of biotech and pharma customers already using Claude. The company's existing strength in coding tools and AI models gives it credibility in computational work, but drug development requires expertise far beyond software engineering.

The Verge first reported these developments following Anthropic's announcement at the AI for Science event.